Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Unipolar Depression

  • Chapter
  • First Online:
Behavioral Neurobiology of Depression and Its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 14))

Abstract

Antidepressants were first developed serendipitously 60 years ago and gave rise to the monoamine hypothesis of depression and antidepressant action which has persisted in various forms ever since. Although we have made huge strides in our understanding of the pharmacology of antidepressants, and in the neuroscience of depression, our current antidepressants have changed little since the original drugs. In this chapter I first review some controversies in the use of antidepressant drugs including whether they actually work, and then go on to describe the current state of our clinical use of antidepressants, looking both at the principles and practice of treatment and reviewing the evidence for efficacy, tolerability and safety in acute and sequenced treatments. I finally briefly consider future directions and the aspiration of developing more effective antidepressants.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adli M, Baethge C, Heinz A et al (2005) Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255:387–400

    Article  PubMed  Google Scholar 

  • Anderson IM (2001) Meta-analytical studies on new antidepressants. Br Med Bull 57:161–178

    Article  PubMed  CAS  Google Scholar 

  • Anderson IM (2003) Drug treatment of depression: reflections on the evidence. Adv Psychiatr Treat 9:11–20

    Article  Google Scholar 

  • Anderson I (2009) Commentary on STAR*D: a summary and UK perspective. J Psychopharmacol 23:613–614

    Article  PubMed  Google Scholar 

  • Anderson IM, Haddad PM (2011) Prescribing antidepressants for depression: time to be dimensional and inclusive. Br J Gen Pract 61:50–52

    Article  PubMed  Google Scholar 

  • Anderson IM, Ferrier IN, Baldwin RC et al (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343–396

    Article  PubMed  CAS  Google Scholar 

  • Andrews PW, Kornstein SG, Halberstadt LJ et al (2011) Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2:159 Epub 7 Jul 2011

    Article  PubMed  Google Scholar 

  • Angst J, Stabl M (1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 106(Suppl):S109–S113

    Article  PubMed  Google Scholar 

  • Baldwin DS, Stein DJ, Dolberg OT et al (2009) How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? an exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269–275

    Article  PubMed  CAS  Google Scholar 

  • Ban TA (2001) Pharmacotherapy of mental illness—a historical analysis. Prog Neuropsychopharmacol Biol Psychiatry 25:709–727

    Article  PubMed  CAS  Google Scholar 

  • Barr LC, Heninger GR, Goodman W et al (1997) Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. Biol Psychiatry 41:949–954

    Article  PubMed  CAS  Google Scholar 

  • Bauer M, Adli M, Bschor T et al (2010) Lithium’s emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 62:36–42

    Article  PubMed  CAS  Google Scholar 

  • Blier P, Ward HE, Tremblay P et al (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 167:281–288

    Article  PubMed  Google Scholar 

  • Bostwick JM, Pankratz VS (2000) Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925–1932

    Article  PubMed  CAS  Google Scholar 

  • Brunoni AR, Tadini L, Fregni F (2010) Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. PLoS One 5:9479

    Article  Google Scholar 

  • Carrasco JL, Sandner C (2005) Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 59:1428–1434

    Article  PubMed  CAS  Google Scholar 

  • Cipriani A, Furukawa TA, Salanti G et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758

    Article  PubMed  CAS  Google Scholar 

  • Corya SA, Williamson D, Sanger TM et al (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372

    Article  PubMed  CAS  Google Scholar 

  • Curry J, Silva S, Rohde P et al (2011) Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry 68:263–269

    Article  PubMed  Google Scholar 

  • Eyding D, Lelgemann M, Grouven U et al (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737. doi:10.1136/bmj.c4737

    Article  PubMed  Google Scholar 

  • Fava M, Rush AJ, Wisniewski SR et al (2006) A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 163:1161–1172

    Article  PubMed  Google Scholar 

  • Food and Drug Administration (2011) FDA Drug Safety Communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Safety Announcement [08-24-2011]. http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm

  • Fountoulakis KN, Moller HJ (2011) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405–412

    Article  PubMed  CAS  Google Scholar 

  • Fournier JC, DeRubeis RJ, Hollon SD et al (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303:47–53

    Article  PubMed  CAS  Google Scholar 

  • Friedman ES, Anderson IM (2010) Managing depression in clinical practice. Springer-Verlag, London

    Book  Google Scholar 

  • Gartlehner G, Hansen RA, Morgan LC et al (2011) Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 155:772–785

    PubMed  Google Scholar 

  • Geddes JR, Carney SM, Davies C et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661

    Article  PubMed  CAS  Google Scholar 

  • Gelenberg AJ, Thase ME, Meyer RE et al (2008) The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry 69:1513–1528

    Article  PubMed  Google Scholar 

  • Guzzetta F, Tondo L, Centorrino F et al (2007) Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 68:380–383

    Article  PubMed  Google Scholar 

  • Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332–339

    Article  PubMed  CAS  Google Scholar 

  • Hawton K, Bergen H, Simkin S et al (2010) Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 196:354–358

    Article  PubMed  Google Scholar 

  • Hickie IB, Rogers NL (2011) Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621–631

    Article  PubMed  CAS  Google Scholar 

  • Holtzheimer PE, Mayberg HS (2011) Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 34:1–9

    Article  PubMed  CAS  Google Scholar 

  • Keers R, Uher R, Huezo-Diaz P et al (2011) Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 11:138–145

    Article  PubMed  CAS  Google Scholar 

  • Keller MB (2003) Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:3152–3160

    Article  PubMed  Google Scholar 

  • Kennedy SH, Andersen HF, Thase ME (2009) Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25:161–175

    Article  PubMed  CAS  Google Scholar 

  • King M, Nazareth I, Lampe F et al (2005) Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA 293:1089–1099

    Article  PubMed  CAS  Google Scholar 

  • Kirsch I, Moncrieff J (2007) Clinical trials and the response rate illusion. Contemp Clin Trials 28:348–351

    Article  PubMed  Google Scholar 

  • Kirsch I, Deacon BJ, Huedo-Medina TB et al (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 5:e45

    Google Scholar 

  • Kocsis JH, Leon AC, Markowitz JC et al (2009) Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry 70:354–361

    Article  PubMed  CAS  Google Scholar 

  • Lin P, Campbell DG, Chaney EF et al (2005) The influence of patient preference on depression treatment in primary care. Ann Behav Med 30:164–173

    Article  PubMed  Google Scholar 

  • McCabe C, Mishor Z, Cowen PJ et al (2010) Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 67:439–445

    Article  PubMed  CAS  Google Scholar 

  • McGrath PJ, Stewart JW, Fava M et al (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 163:1531–1541

    Article  PubMed  Google Scholar 

  • McIntyre RS, Muzina DJ, Adams A et al (2009) Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 10:3061–3075

    Article  PubMed  CAS  Google Scholar 

  • Melander H, Salmonson T, Abadie E et al (2008) A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623–627

    Article  PubMed  CAS  Google Scholar 

  • Mergl R, Henkel V, Allgaier AK et al (2011) Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? results from a randomized controlled trial including a patients’ choice arm. Psychother Psychosom 80:39–47

    Article  PubMed  Google Scholar 

  • Middleton H, Moncrieff J (2011) ‘They won’t do any harm and might do some good’: time to think again on the use of antidepressants? Br J Gen Pract 61:47–49

    Article  PubMed  Google Scholar 

  • Moller HJ, Bitter I, Bobes J et al (2012) Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. Eur Psychiatry 27:114–128

    Google Scholar 

  • Moncrieff J (2006) Why is it so difficult to stop psychiatric drug treatment? it may be nothing to do with the original problem. Med Hypotheses 67:517–523

    Article  PubMed  CAS  Google Scholar 

  • Moncrieff J, Wessely S, Hardy R (2004) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev CD003012

    Google Scholar 

  • National Institute for Health and Clinical Excellence (2009a) Clinical guideline 90. Depression in adults (update): full guideline. http://guidance.nice.org.uk/CG90/Guidance

  • National Institute for Health and Clinical Excellence (2009b) Clinical guideline 91. Depression in adults with a chronic health problem: full guideline. http://guidance.nice.org.uk/CG91/Guidance

  • Newnham EA, Hooke GR, Page AC (2010) Progress monitoring and feedback in psychiatric care reduces depressive symptoms. J Affect Disord 127:139–146

    Article  PubMed  Google Scholar 

  • Nierenberg AA, McLean NE, Alpert JE et al (1995) Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152:1500–1503

    PubMed  CAS  Google Scholar 

  • Nierenberg AA, Farabaugh AH, Alpert JE et al (2000) Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157:1423–1428

    Article  PubMed  CAS  Google Scholar 

  • Nierenberg AA, Fava M, Trivedi MH et al (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519–1530

    Article  PubMed  Google Scholar 

  • Nutt DJ (2009) Beyond psychoanaleptics—can we improve antidepressant drug nomenclature? J Psychopharmacol 23:343–345

    Article  PubMed  CAS  Google Scholar 

  • Opbroek A, Delgado PL, Laukes C et al (2002) Emotional blunting associated with SSRI-induced sexual dysfunction: do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 5:147–151

    Article  PubMed  CAS  Google Scholar 

  • Papakostas GI, Shelton RC, Smith J et al (2007a) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826–831

    Article  PubMed  CAS  Google Scholar 

  • Papakostas GI, Thase ME, Fava M et al (2007b) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217–1227

    Article  PubMed  CAS  Google Scholar 

  • Papakostas GI, Fava M, Thase ME (2008a) Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63:699–704

    Article  PubMed  CAS  Google Scholar 

  • Papakostas GI, Nelson JC, Kasper S et al (2008b) A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 18:122–127

    Article  PubMed  CAS  Google Scholar 

  • Papakostas GI, Charles D, Fava M (2010) Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 11:300–307

    Article  PubMed  Google Scholar 

  • Portella MJ, de Diego-Adelino J, Ballesteros J et al (2011) Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? a randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 72:962–969

    Article  PubMed  Google Scholar 

  • Posternak MA, Zimmerman M (2005) Is there a delay in the antidepressant effect? a meta-analysis. J Clin Psychiatry 66:148–158

    Article  PubMed  CAS  Google Scholar 

  • Posternak MA, Zimmerman M (2007) Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 190(287–92):287–292

    Article  PubMed  Google Scholar 

  • Pratt L, Brody D, Gu Q (2011) Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS data brief, no 76. National Center for Health Statistics, Hyattsville. http://www.cdc.gov/nchs/data/databriefs/db76.htm

  • Preskorn SH (2010) CNS drug development: part I: the early period of CNS drugs. J Psychiatr Pract 16:334–339

    Article  PubMed  Google Scholar 

  • Preskorn SH (2011) CNS drug development: part III: future directions. J Psychiatr Pract 17:49–52

    Article  PubMed  Google Scholar 

  • Price J, Cole V, Goodwin GM (2009) Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 195:211–217

    Article  PubMed  Google Scholar 

  • Quitkin FM, Petkova E, McGrath PJ et al (2003) When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160:734–740

    Article  PubMed  Google Scholar 

  • Rubino A, Roskell N, Tennis P et al (2007) Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 334:242

    Article  PubMed  CAS  Google Scholar 

  • Rudolph RL, Fabre LF, Feighner JP et al (1998) A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116–122

    Article  PubMed  CAS  Google Scholar 

  • Ruhe HG, Huyser J, Swinkels JA et al (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836–1855

    Article  PubMed  CAS  Google Scholar 

  • Ruhe HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331–359

    Article  PubMed  CAS  Google Scholar 

  • Rush AJ (2007) STAR*D: what have we learned? Am J Psychiatry 164:201–204

    Article  PubMed  Google Scholar 

  • Rush AJ, Trivedi MH, Wisniewski SR et al (2006a) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917

    Article  PubMed  Google Scholar 

  • Rush AJ, Trivedi MH, Wisniewski SR et al (2006b) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242

    Article  PubMed  CAS  Google Scholar 

  • Rush AJ, Trivedi MH, Stewart JW et al (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689–701

    Article  PubMed  Google Scholar 

  • Serretti A, Chiesa A (2009) Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 29:259–266

    Article  PubMed  CAS  Google Scholar 

  • Shelton RC, Williamson DJ, Corya SA et al (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66:1289–1297

    Article  PubMed  CAS  Google Scholar 

  • Simon GE, Perlis RH (2010) Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 167:1445–1455

    Article  PubMed  Google Scholar 

  • Simon GE, Savarino J (2007) Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 164:1029–1034

    Article  PubMed  Google Scholar 

  • Sinyor M, Levitt AJ, Cheung AH et al (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? results from pooled and meta-analyses. J Clin Psychiatry 71:270–279

    Article  PubMed  CAS  Google Scholar 

  • Smith D, Dempster C, Glanville J et al (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180(396–404):396–404

    Article  PubMed  Google Scholar 

  • Stone M, Laughren T, Jones ML et al (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US food and drug administration. BMJ 339:b2880. doi:10.1136/bmj.b2880

    Article  PubMed  Google Scholar 

  • Szegedi A, Jansen WT, van Willigenburg AP et al. (2009) Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 70:344–353

    Google Scholar 

  • Tanti A, Belzung C (2010) Open questions in current models of antidepressant action. Br J Pharmacol 159:1187–1200

    Article  PubMed  CAS  Google Scholar 

  • Thase ME, Shelton RC, Khan A (2006) Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 26:250–258

    Article  PubMed  CAS  Google Scholar 

  • Thase ME, Friedman ES, Biggs MM et al (2007) Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 164:739–752

    Article  PubMed  Google Scholar 

  • Thase ME, Larsen KG, Kennedy SH (2011) Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry 199:501–507

    Article  PubMed  Google Scholar 

  • Trivedi MH, Rush AJ, Crismon ML et al (2004) Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 61:669–680

    Article  PubMed  Google Scholar 

  • Trivedi MH, Fava M, Wisniewski SR et al (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252

    Article  PubMed  CAS  Google Scholar 

  • Turner EH, Matthews AM, Linardatos E et al (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252–260

    Article  PubMed  CAS  Google Scholar 

  • Uher R, Maier W, Hauser J et al (2009) Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 194:252–259

    Article  PubMed  Google Scholar 

  • Zarate CA Jr, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864

    Article  PubMed  CAS  Google Scholar 

  • Zhong H, Haddjeri N, Sanchez C (2012) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. Psychopharmacology 219:1–13

    Article  PubMed  CAS  Google Scholar 

  • Zimmerman M, McGlinchey JB, Posternak MA et al (2006) How should remission from depression be defined? the depressed patient’s perspective. Am J Psychiatry 163:148–150

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroscience and Psychiatry Unit, Manchester Academic Health Science Centre, University of Manchester, Room G809, Stopford Building, Oxford Road, Manchester, M13 9PT, UK

    Ian M. Anderson

Authors
  1. Ian M. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian M. Anderson .

Editor information

Editors and Affiliations

  1. Warneford Hospital, Dept. Psychiatry, University of Oxford, Oxford, OX3 7JX, United Kingdom

    Philip J. Cowen

  2. Dept. Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, United Kingdom

    Trevor Sharp

  3. , Dep of Experimental Psychology, University of Oxford, South Parks Road, Oxford, OX1 3UD, United Kingdom

    Jennifer Y. F. Lau

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Anderson, I.M. (2012). Pharmacological Treatment of Unipolar Depression. In: Cowen, P., Sharp, T., Lau, J. (eds) Behavioral Neurobiology of Depression and Its Treatment. Current Topics in Behavioral Neurosciences, vol 14. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2012_208

Download citation

Publish with us

Policies and ethics

Search

Navigation